Skye Bioscience, Inc.
SKYEHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeSkye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. At a $8.3M market cap, Skye Bioscience, Inc. ranks as a micro-cap company within healthcare. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.
Market Cap
$8.3M
Beta
2.90
P/E (TTM)
—
P/E (Fwd)
-0.25
EPS (TTM)
$-9.97
EPS (Fwd)
$-7.40
ROE
-233.9%
ROA
-95.1%
Cash
$10.1M
Total Debt
$178,746
Free CF
-$18.7M
52W Change
-94.4%
Annual Financials
Cash vs Debt
Where SKYE stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SKYE finished 135.90% above its 150-day moving average ($0.78) and 116.47% above its 200-day moving average ($0.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SKYE overbought or oversold?
At the September 3, 2026 close, SKYE's RSI(14) was 73.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $10.1M in cash comfortably exceeding the $179K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$18.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -233.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 2.90 means SKYE is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, SKYE has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Skye Bioscience, Inc.'s trajectory.